Analyst firms · Citigroup · ALAB
Citigroup ALAB price target and rating history
Astera Labs Inc. (ALAB) · Technology
Citigroup rates Astera Labs Inc. (ALAB) Buy with a $200 price target, as of its latest action on Apr 3, 2026. It has published 3 rating actions on ALAB since November 2024, including 0 upgrades and 0 downgrades. Across 7 firms with a ALAB price target in the last 12 months, the median target is $225. Citigroup's $200 is 11% below that.
- Current rating
- Buy
- Price target
- $200
- Median target, all firms
- $225
- Actions on ALAB
- 3
Citigroup price target on ALAB
Every Citigroup rating on ALAB
- Apr 3, 2026
- Apr 2, 2026
- Nov 18, 2024
How other firms rate ALAB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BMO Capital Markets | Outperform | $375 | Nov 5, 2026 |
| Northland Capital Markets | Outperform | $315 | Nov 4, 2026 |
| Rothschild & Co Redburn | Neutral | $153 | May 1, 2026 |
| UBS | Neutral | $180 | Apr 21, 2026 |
| Citigroup | Buy | $200 | Apr 3, 2026 |
| Loop Capital | Buy | $250 | Mar 5, 2026 |
| RBC Capital Markets | Outperform | Jan 15, 2026 | |
| Raymond James | Mkt Perform | Nov 21, 2025 | |
| BNP Paribas Exane | Outperform | $225 | Nov 20, 2025 |
Questions about Citigroup and ALAB
- What is Citigroup's price target for ALAB?
- Citigroup's latest stated price target for Astera Labs Inc. (ALAB) is $200, from its action on Apr 3, 2026.
- What is Citigroup's rating on ALAB?
- Citigroup rates ALAB Buy, a bullish rating, as of Apr 3, 2026.
- When did Citigroup last change its view on ALAB?
- On Apr 3, 2026, Citigroup starts coverage at Buy, price target $200.
- How does Citigroup's ALAB target compare with other analysts?
- Across 7 firms with a ALAB price target in the last 12 months, the median target is $225. Citigroup's $200 is 11% below that.
More ALAB rating histories
All Citigroup ratingsALAB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.